Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Operating Expenses (2018 - 2025)

Inmune Bio's Operating Expenses history spans 8 years, with the latest figure at $7.4 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 39.5% year-over-year to $7.4 million; the TTM value through Sep 2025 reached $51.4 million, up 23.65%, while the annual FY2024 figure was $42.6 million, 42.66% up from the prior year.
  • Operating Expenses for Q3 2025 was $7.4 million at Inmune Bio, down from $24.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $24.6 million in Q2 2025 and bottomed at $4.6 million in Q1 2021.
  • The 5-year median for Operating Expenses is $8.4 million (2023), against an average of $9.0 million.
  • The largest annual shift saw Operating Expenses surged 211.06% in 2021 before it tumbled 39.5% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $9.2 million in 2021, then tumbled by 37.57% to $5.7 million in 2022, then skyrocketed by 46.49% to $8.4 million in 2023, then increased by 12.61% to $9.5 million in 2024, then fell by 21.49% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Operating Expenses are $7.4 million (Q3 2025), $24.6 million (Q2 2025), and $10.0 million (Q1 2025).